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respectively, reverted anti-apoptotic or anti-senescent Vit.D 
properties. SirT1 protein expression levels were up-regulated 
by Vit.D. ERKs inhibition blocked Vit.D-induced SirT1 protein 
up-regulation in proliferating cells. In quiescent HUVEC cells, 
p38 inhibition counteracted the IR-induced SirT1 protein 
down-regulation, while MKK6 transfection abrogated the 
Vit.D positive effects on SirT1 protein levels after irradiation. 
SirT1 inhibition by sirtinol blocked the Vit.D radioprotective 
effects. 
 
Conclusion: Vit.D protects HUVEC from IR induced/oxidative 
stress by positively regulating the MAPKs/SirT1 axis. 
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Purpose or Objective: Trials of amifostine in patients with 
advanced non-small cell lung cancer (NSCLC) receiving 
chemoradiotherapy (CRT) or radiotherapy (RT) alone report 
varying treatment-related toxicity. A review and meta-
analysis was conducted to examine amifostine’s effect on 
toxicity and efficacy of CRT or RT alone in such patients. 
 
Material and Methods: Searches of electronic databases 
yielded 16 eligible trials comprising 1057 patients. Data 
extracted from randomised and non-randomised trials were 
compiled in a review; results of randomised trials were 
pooled and using meta-analyses to estimate the effect of 
amifostine on treatment toxicity and efficacy.  
 
Results: Amifostine reduced the risk of >Grade 2 acute 
oesophagitis by 26% (risk ratio [RR], 0.74; 95% confidence 
interval [CI], 0.65-0.86; p<0.0001) and the risk of acute 
pulmonary toxicity by 44% (RR, 0.56; 95%CI, 0.41-0.75; 
p=0.0001). Amifostine did not alter risk of late pulmonary 
toxicity (RR, 0.84; 95% CI, 0.65-1.08; p=0.17). Risk of 
complete response was unchanged (RR, 1.64; 95% CI, 0.99-
2.73; p=0.06), partial response was unchanged (RR, 0.92; 95% 
CI, 0.73-1.16; p=0.48). Statistical heterogeneity was high for 
toxicity but low for response. Non-randomised trials reported 
varying incidence of toxicities and survival/response. Studies 
were medium-high quality. 
 
Conclusion: Statistical heterogeneity casts doubt over 
amifostine’s efficacy in this setting, despite evidence of 
decreased incidence of acute oesophageal and pulmonary 
toxicity but not late pulmonary toxicity. Amifostine did not 
compromise CRT or RT efficacy.  
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Purpose or Objective: It is well known that proton therapy 
generates a small but significant exposure to scattered 
neutrons. The success of paediatric proton treatments leads 
to a concern about second cancers arising in later life from 
the neutron exposure. However there are difficulties involved 
with estimating the risk from exposure to neutrons. The usual 
approach is through the concept of relative biological 
effectiveness (RBE) of neutrons compared to photons, since 
the risk from photon exposure is much better known (ICRP 
Publication 103. Ann. ICRP 37 (2-4), 2007) The RBE for 
neutrons has been evaluated using cellular and animal 
models. But this causes uncertainty when applying the 
method to humans. The ANDANTE project 
(http://www.andanteproject.eu/) has investigated the 
relative risk of cancer from neutrons compared to photons in 
the context of proton therapy, using three different 
disciplines in parallel.  
 
Material and Methods: Physics: Charged particle spectra 
generated by both neutron and photon beams were 
characterised using Monte Carlo simulation and 
measurements. A track structure model was used to model 
the formation of complex lesions in DNA from the different 
spectra as an indicator of relative likelihood of cancer 
induction. A method was developed for reconstructing the 
scattered neutron doses outside the treatment volume during 
proton therapy, using available clinical data, in order to be 
able to predict second cancer risks. Stem cell radiobiology: 
Stem cells from thyroid, salivary gland, and breast tissue 
were given well characterised exposures to both broad- and 
narrow-spectrum neutron beams, and to 200 kV X-rays. The 
relative risk of damage from neutrons compared to photons 
was estimated using a number of endpoints. Part of the cell 
population was transplanted into mice. Detailed 
histopathological and molecular investigations were 
performed looking for pre-malignant lesions and signs of 
malignancy. Epidemiology: The results from the track 
structure modelling and stem cell experiments were 
combined to generate a relative risk model. Dose 
reconstruction and data analysis tools were developed for a 
multi-centre prospective epidemiological study using data 
from paediatric proton therapy treatments, which will test 
the relative risk model. The project has made initial plans for 
the study as a collaboration between centres in Europe and 
the USA. 
 
Results: The track structure model reproduced the peak in 
relative risk between neutrons and photons at a neutron 
energy of around 1 MeV, similar to the ICRP model. The stem 
cell experiments successfully demonstrated a new 
methodology, but did not provide conclusive evidence to 
contradict the ICRP model. The feasibility of a prospective 
epidemiological study was demonstrated. 
 
Conclusion: The results from the ANDANTE project do not 
contradict ICRP. In the longer term, the prospective study 
will provide greater certainty on the RBE for neutrons and 
how this applies to humans receiving proton therapy. 
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Purpose or Objective: Radiation-induced fibrosis is a delayed 
complication of radiotherapy often associated with chronic 
inflammatory process and macrophage infiltration. 
Nowadays, macrophages are suggested to be important 
cellular contributors to fibrogenic process, but their 
implication in the context of RIF is not well known. 
 
Material and Methods: To investigate the role of 
macrophages in RIF we have used a classical experimental 
model of lung fibrosis developed in C57Bl/6 mice after 16Gy 
thorax-IR. We then profiled both alveolar macrophages (AM) 
and interstitial macrophages (IM) during the various steps of 
the fibrogenic process. 
 
Results: We confirmed the fact that total lung irradiation at 
16Gy (IR) induces an interstitial fibrosis associated with 
delayed recruitment of pulmonary macrophages.  
We found a transient depletion of AM associated with 
cytokine secretion during the acute post-IR phase (15 days), 
followed by an active repopulation and an enhanced number 
of AM during the late post-IR phase (20 weeks). Interestingly, 
AM were mostly recruited from the bone marrow and exhibit 
a hybrid polarization (M1/M2) associated with up-regulation 
of Th1 and Th2 cytokines. The number of M2-polarized IM 
significantly increased during the late time points after 
irradiation and a down-regulation of Th1 cytokine was 
measured in tissue lysate. These results suggest a differential 
contribution of hybrid AM vs M2-IM to fibrogenesis. 
Interestingly, in contrast to activated hybrid AM, activated 
